Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
15069 | 664 | 40.0 | 90% |
Classes in level above (level 2) |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | TC 99M ANNEXIN V | Author keyword | 31 | 92% | 2% | 12 |
2 | ANNEXIN V | Author keyword | 20 | 16% | 17% | 111 |
3 | APOPTOSIS IMAGING | Author keyword | 19 | 70% | 2% | 16 |
4 | APOSENSE | Author keyword | 11 | 100% | 1% | 6 |
5 | ZINCII DIPICOLYLAMINE | Author keyword | 8 | 100% | 1% | 5 |
6 | BAVITUXIMAB | Author keyword | 6 | 80% | 1% | 4 |
7 | ZINC DIPICOLYLAMINE | Author keyword | 6 | 100% | 1% | 4 |
8 | C2A | Author keyword | 4 | 75% | 0% | 3 |
9 | ANNEXIN A5 | Author keyword | 4 | 16% | 3% | 21 |
10 | TC 99M DURAMYCIN | Author keyword | 3 | 100% | 0% | 3 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | TC 99M ANNEXIN V | 31 | 92% | 2% | 12 | Search TC+99M+ANNEXIN+V | Search TC+99M+ANNEXIN+V |
2 | ANNEXIN V | 20 | 16% | 17% | 111 | Search ANNEXIN+V | Search ANNEXIN+V |
3 | APOPTOSIS IMAGING | 19 | 70% | 2% | 16 | Search APOPTOSIS+IMAGING | Search APOPTOSIS+IMAGING |
4 | APOSENSE | 11 | 100% | 1% | 6 | Search APOSENSE | Search APOSENSE |
5 | ZINCII DIPICOLYLAMINE | 8 | 100% | 1% | 5 | Search ZINCII+DIPICOLYLAMINE | Search ZINCII+DIPICOLYLAMINE |
6 | BAVITUXIMAB | 6 | 80% | 1% | 4 | Search BAVITUXIMAB | Search BAVITUXIMAB |
7 | ZINC DIPICOLYLAMINE | 6 | 100% | 1% | 4 | Search ZINC+DIPICOLYLAMINE | Search ZINC+DIPICOLYLAMINE |
8 | C2A | 4 | 75% | 0% | 3 | Search C2A | Search C2A |
9 | ANNEXIN A5 | 4 | 16% | 3% | 21 | Search ANNEXIN+A5 | Search ANNEXIN+A5 |
10 | TC 99M DURAMYCIN | 3 | 100% | 0% | 3 | Search TC+99M+DURAMYCIN | Search TC+99M+DURAMYCIN |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | ANNEXIN V | 25 | 13% | 28% | 187 |
2 | TUMOR APOPTOSIS | 25 | 75% | 3% | 18 |
3 | RADIOLABELED ANNEXIN V | 23 | 79% | 2% | 15 |
4 | TC 99M ANNEXIN V | 23 | 79% | 2% | 15 |
5 | EXPERIMENTAL CEREBRAL STROKE | 23 | 100% | 2% | 10 |
6 | ANNEXIN V SCINTIGRAPHY | 21 | 71% | 3% | 17 |
7 | PHOSPHATIDYLSERINE EXPRESSION | 19 | 21% | 12% | 81 |
8 | IN VIVO DETECTION | 16 | 18% | 12% | 79 |
9 | TC 99M LABELED C2A DOMAIN | 14 | 100% | 1% | 7 |
10 | BINDS ANIONIC PHOSPHOLIPIDS | 10 | 47% | 2% | 16 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
In vivo detection of apoptosis | 2008 | 74 | 125 | 58% |
Beyond annexin V: fluorescence response of cellular membranes to apoptosis | 2013 | 14 | 83 | 40% |
Apoptosis Imaging to Monitor Cancer Therapy: The Road to Fast Treatment Evaluation? | 2012 | 11 | 68 | 63% |
Biomarkers and Molecular Probes for Cell Death Imaging and Targeted Therapeutics | 2012 | 16 | 208 | 45% |
Monitoring of Treatment-Induced Apoptosis in Oncology with PET and SPECT | 2008 | 20 | 76 | 68% |
In vivo imaging of apoptosis | 2008 | 25 | 82 | 59% |
Molecular imaging of cell death | 2009 | 40 | 103 | 33% |
Apoptosis-detecting radioligands: current state of the art and future perspectives | 2004 | 144 | 206 | 25% |
Multimodality Molecular Imaging of Apoptosis in Oncology | 2011 | 11 | 101 | 44% |
Comparison of different probes based on labeled annexin V for detection of apoptosis | 2014 | 1 | 72 | 54% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | JIANGSU TARGET PHARMA S INC | 3 | 60% | 0.5% | 3 |
2 | HAMON CANC | 3 | 42% | 0.8% | 5 |
3 | GLAUCOMA RETINAL NEURODEGENERAT GRP | 2 | 36% | 0.6% | 4 |
4 | COMPREHENS CANC IMAGING SURG CANC | 1 | 50% | 0.3% | 2 |
5 | DRUG TARGETING ANAL | 1 | 50% | 0.3% | 2 |
6 | MED SIGNAL | 1 | 100% | 0.3% | 2 |
7 | TRANSLAT NUCL MED MOL IMAGING | 1 | 22% | 0.6% | 4 |
8 | MOL IMAGING BIOMARKER | 1 | 33% | 0.3% | 2 |
9 | UMR S773 | 1 | 33% | 0.3% | 2 |
10 | CELLS MOT CLUSTER EXCELLENCE EXC CIM 1003 | 1 | 50% | 0.2% | 1 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000133878 | MFG E8//APOPTOTIC CELLS//CELL CLEARANCE |
2 | 0.0000105791 | ANTIMYOSIN ANTIBODY//TC 99M GLUCARATE//ANTIMYOSIN SCINTIGRAPHY |
3 | 0.0000099862 | APOPTOSIS REPRESSOR WITH CASPASE RECRUITMENT DOMAIN//CARDIAC OUTPUT INDEX//EXP CARDIOL |
4 | 0.0000097330 | AMINOPHOSPHOLIPID TRANSLOCASE//PHOSPHOLIPID ASYMMETRY//FLIPPASE |
5 | 0.0000095515 | F 18 FLT//F 18FLT//FLT |
6 | 0.0000090142 | PHARMACEUT CARE CLIN PHARM//BRAIN NEURON//BISABOLOLOXIDE A |
7 | 0.0000084739 | ANNEXIN//ANNEXIN A1//ANNEXIN 1 |
8 | 0.0000084199 | LASER SCANNING CYTOMETRY//MOL PATTERN RECOGNIT GRP//LASER SCANNING CYTOMETRY LSC |
9 | 0.0000074275 | HIGH MOLECULAR WEIGHT DNA FRAGMENTATION//CA2 MG2 DEPENDENT ENDONUCLEASE//APO27 |
10 | 0.0000072881 | FLUORINE 18//F 18SFB//RADIOFLUORINATION |